6.00
0.47 (8.41%)
| Penutupan Terdahulu | 5.53 |
| Buka | 5.60 |
| Jumlah Dagangan | 22,817 |
| Purata Dagangan (3B) | 26,014 |
| Modal Pasaran | 56,351,880 |
| Harga / Pendapatan (P/E TTM) | 37.50 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 20 Mar 2025 - 24 Mar 2025 |
| Margin Keuntungan | -232.86% |
| Margin Operasi (TTM) | -37,942.86% |
| EPS Cair (TTM) | 0.160 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -53.10% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -19.60% |
| Nisbah Semasa (MRQ) | 0.400 |
| Aliran Tunai Operasi (OCF TTM) | -12.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -7.45 M |
| Pulangan Atas Aset (ROA TTM) | -86.74% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Serina Therapeutics, Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | 1.5 |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.80 |
|
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 69.70% |
| % Dimiliki oleh Institusi | 3.37% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Broadwood Capital Inc | 30 Sep 2024 | 85,219 |
| Keel Point, Llc | 30 Sep 2024 | 17,774 |
| Piscataqua Savings Bank | 30 Sep 2024 | 28 |
| Riggs Asset Managment Co. Inc. | 30 Sep 2024 | 24 |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BAILEY GREGORY | 4.79 | - | 3,866 | 18,518 |
| Jumlah Keseluruhan Kuantiti Bersih | 3,866 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | 18,518 | |||
| Purata Pembelian Keseluruhan ($) | 4.79 | |||
| Purata Jualan Keseluruhan ($) | - | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BAILEY GREGORY | Pengarah | 17 Dec 2024 | Beli (+) | 3,866 | 4.79 | 18,518 |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 16 Dec 2024 | Pengumuman | Serina Therapeutics to Present at Tribe Public’s Webinar Event "Enabling Continuous Drug Delivery for Parkinson's Disease & Beyond" on Wednesday, December 18, 2024 |
| 11 Dec 2024 | Pengumuman | Serina Therapeutics to Present at the 3rd Annual LNP Immunogenicity & Toxicity Summit |
| 02 Dec 2024 | Pengumuman | Serina Therapeutics Secures $10 Million Financing to Continue Advancing Lead IND Candidate into Phase 1 Clinical Trial in Advanced Parkinson's Disease Patients |
| 12 Nov 2024 | Pengumuman | Serina Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Highlights |
| 11 Nov 2024 | Pengumuman | Serina Therapeutics Makes Grants to New Employees Under Inducement Plan |
| 02 Oct 2024 | Pengumuman | Serina Therapeutics to Present at the 14th Annual Injectables Summit |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |